The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OXB | +99.75% | -19.58% | -4.26% | -59% |
| S&P | +13.95% | +78.35% | +12.25% | +862% |
OXB is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US.
No news articles found for OXB.
No data available for this period.
Currently no data to display
Currently no data to display.
Currently no data to display.
No data available for this period.
No data available for this period.
No data available for this period.
No data available for this period.
| Metric | YoY Change |
|---|
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
